BioCytics is developing a personalized immuno-oncology platform designed to isolate, expand, and re-invigorate a patient's own immune cells to combat cancer. To ensure these cells are primed for tumor destruction, the company is utilizing Eremid’s specialized capabilities in single-cell RNA sequencing and TCR sequencing. This data will provide a granular look at the mechanisms behind the cells' expansion and confirm their readiness for reinfusion.

Dr. Renaud Warin, CSO at BioCytics, noted that these molecular insights are essential for validating the therapy’s stability across diverse patient samples. Beyond immediate clinical validation, the study intends to refine predictive models for anti-cancer responses based on individual immune profiles. For Eremid, the partnership represents a strategic application of their CLIA-certified genomic expertise, supporting the development of non-genetically modified effector cells intended to treat solid tumors at various stages.